Intervention

Pneumococcal polysaccharide vaccine

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 2 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials2

Recruiting0

Common conditions3

Lead sponsors shown2

Clinical trials

2 shown

Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying TherapyNCT05028634 · 2021-11-11

COMPLETED

Immune System Function Following Vaccination in HIV Infected Children Taking Anti-HIV DrugsNCT00257127 · 2006-02-01

COMPLETED

Common conditions

HIV Infections1 Multiple Sclerosis1 Multiple Sclerosis, Relapsing-Remitting1

Leading sponsors

Celgene 1 National Institute of Allergy and Infectious Diseases (NIAID) 1

Trial status mix

COMPLETED2

Phase mix

NA1

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.